Ominsky MS - Search Results

1

Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus.

Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC. Hamann C, et al. Among authors: ominsky ms. J Bone Miner Res. 2013 Mar;28(3):627-38. doi: 10.1002/jbmr.1803. J Bone Miner Res. 2013. PMID: 23109114 Free article.

2

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Li X, et al. Among authors: ominsky ms. J Bone Miner Res. 2010 Dec;25(12):2647-56. doi: 10.1002/jbmr.182. Epub 2010 Jul 16. J Bone Miner Res. 2010. PMID: 20641040 Free article.

3

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Ominsky MS, et al. J Bone Miner Res. 2011 May;26(5):1012-21. doi: 10.1002/jbmr.307. J Bone Miner Res. 2011. PMID: 21542004 Free article.

4

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Li X, et al. Among authors: ominsky ms. J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216. J Bone Miner Res. 2008. PMID: 18269310 Free article.

5

One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength.

Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. Ominsky MS, et al. J Bone Miner Res. 2009 Jul;24(7):1234-46. doi: 10.1359/jbmr.090215. J Bone Miner Res. 2009. PMID: 19257823 Free article.

6

Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Li X, et al. Among authors: ominsky ms. Endocrinology. 2011 Sep;152(9):3312-22. doi: 10.1210/en.2011-0252. Epub 2011 Jul 5. Endocrinology. 2011. PMID: 21733832

7

Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene.

Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ, Lee E, Liu M, Simonet WS, Paszty C, Ke HZ. Li C, et al. Among authors: ominsky ms. Bone. 2011 Dec;49(6):1178-85. doi: 10.1016/j.bone.2011.08.012. Epub 2011 Aug 26. Bone. 2011. PMID: 21890008

8

Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model.

Alaee F, Virk MS, Tang H, Sugiyama O, Adams DJ, Stolina M, Dwyer D, Ominsky MS, Ke HZ, Lieberman JR. Alaee F, et al. Among authors: ominsky ms. J Orthop Res. 2014 Feb;32(2):197-203. doi: 10.1002/jor.22498. Epub 2013 Nov 8. J Orthop Res. 2014. PMID: 24600701 Free article.

9

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.

Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ. Stolina M, et al. Among authors: ominsky ms. Bone. 2014 Oct;67:305-13. doi: 10.1016/j.bone.2014.07.031. Epub 2014 Aug 2. Bone. 2014. PMID: 25093263

10

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ. Li X, et al. Among authors: ominsky ms. Endocrinology. 2014 Dec;155(12):4785-97. doi: 10.1210/en.2013-1905. Epub 2014 Sep 26. Endocrinology. 2014. PMID: 25259718

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page